Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Myasthenia Gravis × Immunoglobulins, Intravenous × Clear all

Phase

Phase 4 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Urologic Neoplasms 1 Neoplasms 1 Myasthenia Gravis 1 Melanoma 1 Limbic Encephalitis 1 Hematologic Neoplasms 1 Epilepsy 1 Epilepsies, Partial 1 Drug Resistant Epilepsy 1 Colonic Neoplasms 1 Autoimmune Diseases of the Nervous System 1 Autoimmune Diseases 1

Interventions

Rituximab 2 Hizentra 2 zilucoplan 1 thymoglobulin 1 rozanolixizumab 1 rhoA GTP-Binding Protein 1 prednylidene 1 inebilizumab 1 gamma-Globulins 1 efgartigimod alfa 1 eculizumab 1 deltacortene 1 carmustine, poliferprosan 20 drug combination 1 apraclonidine 1 Sternotomy 1 Prednisone 1 Peripheral Blood Stem Cell Transplantation 1 Methotrexate 1 Melphalan 1 Immunoglobulins, Intravenous 1 HBM9161 1 Fluid Therapy 1 Etoposide 1 Cytarabine 1 Carmustine 1 CK-2017357 1 Bortezomib 1 Antilymphocyte Serum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04728425 2025-04-27

MG_SCIG

University Health Network, Toronto

Phase 2 Completed

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡